Indian pharma stocks slide as Trump outlines tariffs of up to 200% on generic drugs
Aurobindo Pharma, Sun Pharma, Cipla and peers fell after a proposed US tariff roadmap put imported generics at risk. A two-year zero-duty window offers Indian exporters time to build US capacity or partnerships before duties are slated to rise to 100% in 2028 and 200% in 2029.
What happened
Aurobindo Pharma · Indian pharma stocks fell after Trump proposed phased US tariffs on imported generic drugs. The two-year duty-free window gives exporters
Key facts
- Nifty Pharma fell nearly 2% in opening trade
- Aurobindo Pharma fell 3.48% to Rs 1,525.50
- Cipla and Lupin each fell 2.5%
- Generic-drug tariff remains 0% for two years
- US tariff rises to 100% on August 1, 2028
- US tariff rises to 200% on August 1, 2029
- Generics account for nearly 90% of US prescriptions
Why this matters
US manufacturing acquisitions, contract-production alliances and supply-chain partnerships have become more urgent for Indian pharma companies seeking to preserve generic-drug access ahead of potential 2028–29 duties.
What to watch
- Official tariff text, product coverage, country exemptions, implementation dates and whether tariffs apply to finished doses, APIs, packaging or all pharma imports.
- Statements from the FDA, HHS, CMS, major US wholesalers and pharmacy retailers on supply-shortage and consumer-price implications.
- Indian companies' quarterly disclosures of US revenue mix, US manufacturing capacity, inventory plans, capex and contract-manufacturing partnerships.
- Any announced US acquisitions, greenfield plants, technology transfers or long-term supply agreements by Indian generic manufacturers.
- US generic price trends, FDA approval timing for domestic facilities and changes in US buyer tendering behavior.
- Indian drugmakers are likely to map product-level US exposure, prioritize high-volume and high-margin molecules for localization, and seek US contract-manufacturing or acquisition targets.
- Companies may front-load US inventory, subject to shelf-life and working-capital limits, to protect near-term supply and contracts before tariff deadlines.
- Management commentary will likely shift toward US capex, partnership pipelines, manufacturing-transfer timelines and expected margin dilution.
- US pharmacy chains, wholesalers, insurers and hospital buyers may lobby for generic-drug exemptions, citing affordability and supply-security risks.